Repare Therapeutics investors sue over alleged unfair merger deal.

Brodsky & Smith is investigating the acquisition of Repare Therapeutics Inc. by XenoTherapeutics, Inc. and Xeno Acquisition Corp. Shareholders may be eligible for a cash payment of $1.82 per share and a contingent value right. The investigation focuses on whether the Repare Board breached its fiduciary duties by failing to conduct a fair process. Investors can contact Jason Brodsky or Marc Ackerman for more information.